|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-2-7
|
|
pubmed:abstractText |
Imatinib mesylate induces a complete cytogenetic response (CCR) in many patients with chronic myeloid leukemia (CML). However, the ultimate goal of therapy for CML is complete elimination of Philadelphia chromosome positive cells or BCR-ABL rearrangements. We studied molecular responses in CML patients in CCR after imatinib treatment.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
162-8
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16461299-Adult,
pubmed-meshheading:16461299-Aged,
pubmed-meshheading:16461299-Aged, 80 and over,
pubmed-meshheading:16461299-Cytogenetic Analysis,
pubmed-meshheading:16461299-Female,
pubmed-meshheading:16461299-Fusion Proteins, bcr-abl,
pubmed-meshheading:16461299-Humans,
pubmed-meshheading:16461299-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:16461299-Male,
pubmed-meshheading:16461299-Middle Aged,
pubmed-meshheading:16461299-Piperazines,
pubmed-meshheading:16461299-Polymerase Chain Reaction,
pubmed-meshheading:16461299-Pyrimidines,
pubmed-meshheading:16461299-Remission Induction
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
|
|
pubmed:affiliation |
Laboratoire d'hématologie Université Victor Segalen, Bordeaux, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II,
Clinical Trial, Phase III
|
